Also trades as: 2186.HK (HKSE) · $vol 10M
LYPHF OTC
Luye Pharma Group Ltd.
1W: +0.0%
1M: +0.0%
3M: +32.3%
YTD: -27.9%
1Y: +0.8%
3Y: -64.0%
$0.27
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$29.6B
+16.2% ▲
5Y CAGR: +8.9%
Total Liabilities
$13.9B
+15.9% ▲
5Y CAGR: +6.9%
Shareholders Equity
$14.2B
+13.0% ▲
5Y CAGR: +8.9%
Cash & Investments
$6.5B
+6.5% ▲
5Y CAGR: +4.6%
Total Debt
$10.3B
+22.5% ▲
5Y CAGR: +5.1%
Net Debt
$5.4B
+3.8% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $3.9B | $2.4B | $2.3B | $3.2B | $4.9B |
| Short-Term Investments | $1.5B | $3.1B | $3.2B | $1.3B | $1.6B |
| Cash & ST Investments | $5.4B | $5.5B | $5.5B | $6.1B | $6.5B |
| Net Receivables | $1.6B | $1.8B | $1.8B | $2.6B | $4.3B |
| Inventory | $612M | $746M | $773M | $828M | $912M |
| Other Current Assets | $2.3B | $2.4B | $2.2B | $1.1B | $1.3B |
| Total Current Assets | $10.0B | $10.4B | $10.8B | $10.7B | $13.3B |
| Property, Plant & Equip. | $4.3B | $4.6B | $4.9B | $5.1B | $5.9B |
| Goodwill & Intangibles | $5.8B | $6.4B | $7.0B | $5.8B | $7.6B |
| Long-Term Investments | -$1.5B | -$2.5B | -$2.1B | $697M | $926M |
| Other Non-Current Assets | $1.8B | $3.5B | $3.6B | $3.2B | $1.7B |
| Total Non-Current Assets | $10.7B | $12.2B | $13.5B | $14.8B | $16.3B |
| Total Assets | $20.6B | $22.6B | $24.2B | $25.5B | $29.6B |
| — Liabilities — | |||||
| Accounts Payable | $485M | $571M | $560M | $767M | $689M |
| Short-Term Debt | $5.6B | $5.2B | $6.8B | $5.2B | $7.6B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $896M | $1.1B | $1.4B | $1.4B | $990M |
| Total Current Liabilities | $7.2B | $7.3B | $9.5B | $8.1B | $10.8B |
| Long-Term Debt | $4.3B | $4.2B | $2.2B | $3.2B | $2.7B |
| Other Non-Current Liab. | $959M | $1.9B | $1.5B | $596M | $199M |
| Total Non-Current Liabilities | $5.3B | $6.1B | $3.7B | $3.8B | $3.1B |
| Total Liabilities | $12.5B | $13.5B | $13.2B | $12.0B | $13.9B |
| — Equity — | |||||
| Common Stock | $418M | $456M | $457M | $486M | $486M |
| Retained Earnings | $6.2B | $6.1B | $6.7B | $7.4B | $0 |
| Accumulated OCI | $502M | $534M | $254M | $505M | $0 |
| Total Stockholders Equity | $7.9B | $8.5B | $10.2B | $12.5B | $14.2B |
| Total Liabilities & Equity | $20.6B | $22.6B | $24.2B | $25.5B | $29.6B |
| — Key Metrics — | |||||
| Total Debt | $10.0B | $9.5B | $9.1B | $8.4B | $10.3B |
| Net Debt | $6.1B | $7.1B | $6.8B | $5.2B | $5.4B |
| Total Investments | $71M | $582M | $1.1B | $2.0B | $2.5B |